Cardiac Complications of Desmopressin
Desmopressin can cause hypotension with decreased systemic vascular resistance, blood pressure elevation (particularly in patients with coronary artery disease), and rarely thrombotic events including myocardial infarction and coronary vasospasm.
Primary Cardiovascular Effects
Hypotension and Hemodynamic Changes
The most common cardiac complication is hypotension due to decreased systemic vascular resistance 1. In a randomized controlled trial of patients undergoing coronary artery bypass grafting, desmopressin (0.3 mcg/kg over 15 minutes) caused:
- Significant decrease in diastolic blood pressure (50.8 mmHg vs 57.6 mmHg in placebo)
- 20% or greater decrease in mean arterial pressure in 35% of patients (7 of 20) versus only 5% in placebo group
- Mean systemic vascular resistance dropped from 1,006 to 766 dyn·s·cm⁻⁵
This vasodilatory effect occurs despite desmopressin's structural similarity to vasopressin, because its pressor activity is very low compared to its antidiuretic activity.
Hypertension Risk
Conversely, the FDA label warns that at high doses, desmopressin can cause blood pressure elevation 2. The drug label specifically states it "should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease because of possible rise in blood pressure."
Thrombotic Complications
Myocardial Infarction
Rare but serious thrombotic events including myocardial infarction and cardiac arrest have been reported 3. A case report documented a 55-year-old woman who developed cardiac arrest within 60 minutes of desmopressin injection given before renal biopsy. The proposed mechanism involves rapid release of abnormal multimeric forms of von Willebrand factor from endothelium, potentially causing excessive platelet aggregation.
Coronary Vasospasm
Desmopressin can trigger coronary vasospasm in patients with endothelial dysfunction 4. A documented case involved a 60-year-old man who developed coronary spastic angina one week after starting oral desmopressin for nocturnia. Acetylcholine provocation testing confirmed severe coronary spasm with ST elevation. While desmopressin typically dilates coronary vessels in healthy individuals, it may paradoxically provoke vasospasm in those with compromised endothelial function.
Cardiac Performance Effects
In patients with central diabetes insipidus, acute desmopressin deficiency causes increased heart rate and left ventricular contractility (likely compensatory for hypovolemia), with impaired diastolic function 5. Replacement therapy normalizes heart rate and contractility but diastolic dysfunction may persist.
Clinical Context and Safety Profile
The 2025 Association of Anaesthetists guidelines note that desmopressin use in cardiac surgery may reduce blood loss slightly, but "these differences are unlikely to be of clinical importance" 6. A 2025 meta-analysis confirmed reduced bleeding (96.20 mL reduction at 24 hours) but with considerable heterogeneity 7.
Critical safety considerations:
- Use large doses with other pressor agents only with careful hemodynamic monitoring 2
- Avoid in patients with coronary artery insufficiency or hypertensive cardiovascular disease unless benefits clearly outweigh risks
- Be prepared for immediate cardiopulmonary resuscitation when administering to high-risk patients 3
- Screen for potential endothelial dysfunction before use in patients with cardiovascular risk factors 4
Key Pitfalls to Avoid
- Do not assume desmopressin is cardiovascularly neutral - it has both vasodilatory and prothrombotic potential
- Monitor blood pressure during and after infusion, especially in cardiac surgery patients where SVR changes can be clinically significant
- Consider underlying endothelial function - patients with diabetes, hypertension, or vasculitis may be at higher risk for paradoxical coronary vasospasm
- Recognize the biphasic risk - hypotension during infusion versus delayed thrombotic events
The cardiac complications span a spectrum from common hemodynamic changes (hypotension/hypertension) to rare but potentially fatal thrombotic events, requiring vigilant monitoring in at-risk populations.